Infinity Pharmaceuticals, Inc. (INFI)
| Market Cap | 65.50M |
| Revenue (ttm) | 2.04M |
| Net Income (ttm) | -46.07M |
| Shares Out | 89.16M |
| EPS (ttm) | -0.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,960,436 |
| Open | 0.830 |
| Previous Close | 0.834 |
| Day's Range | 0.735 - 0.850 |
| 52-Week Range | 0.460 - 3.890 |
| Beta | 2.18 |
| Analysts | Buy |
| Price Target | 6.19 (+742.5%) |
| Earnings Date | Jul 26, 2022 |
About INFI
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, deve... [Read more...]
Financial Performance
In 2021, INFI's revenue was $1.86 million, an increase of 8.09% compared to the previous year's $1.72 million. Losses were -$45.26 million, 11.8% more than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for INFI stock is "Buy." The 12-month stock price forecast is 6.19, which is an increase of 742.52% from the latest price.
News
Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogr...
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Tops Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 0% and 65.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immu...
Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogr...
JAZZ Stock Surges Almost 30% YTD: What's Driving the Rally?
Strong performance of JAZZ's Xywav and new oncology drugs along with acquired drugs reduced dependence on Xyrem, which will face generic competition shortly.
Infinity Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Company Highlights
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immu...
Infinity Pharmaceuticals Announces the Date of Its Fourth Quarter and Full Year 2021 Financial Results Conference Cal...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogr...
Infinity Pharmaceuticals to Present at the 32nd Annual Oppenheimer Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogr...
Infinity Pharmaceuticals to Be Featured in a Fireside Chat as Part of B. Riley's 2022 Virtual Oncology Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogr...
Infinity to Present at 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity Pharmaceuticals Outlines Eganelisib Clinical Development Strategy and Provides 2022 Guidance
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogra...
Best Penny Stocks To Buy Now? 3 To Watch Before Next Week
3 penny stocks investors decided to buy before next week. Are they on your list right now?
Infinity Pharmaceuticals Added to the NASDAQ Biotechnology Index
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macroph...
Infinity Pharmaceuticals to be Featured in B. Riley Fireside Chat
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS). MARIO-3 Phase 2 trial is evaluating eganel...
Encouraging Updated Data from Phase 2 MARIO-3 TNBC Trial Presented at 2021 San Antonio Breast Cancer Symposium
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogra...
Infinity Pharmaceuticals to Host an Investor Event on Updated MARIO-3 Data Presented at the 2021 San Antonio Breast C...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Are Options Traders Betting on a Big Move in Infinity (INFI) Stock?
Investors need to pay close attention to Infinity (INFI) stock based on the movements in the options market lately.
Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Misses Revenue Estimates
Infinity (INFI) delivered earnings and revenue surprises of 14.29% and -5.31%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Infinity Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”) today announced its third quarter 2021 financial results and provided a corporate update on...
Infinity Announces the Date of Its Third Quarter 2021 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...
Why Infinity Pharmaceuticals Shot Nearly 4% Higher Today
An analyst initiated coverage of the biotech stock with a unambiguous buy recommendation.
Infinity to Participate in Oppenheimer's Fall Healthcare Life Sciences and MedTech Summit and the 3rd Annual Macropha...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrop...